FDA approves subcutaneous Tremfya induction treatment for ulcerative colitis
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.
Sep 25, 2025
0
14








